The Latest Breaking News from Moderna

Moderna cut its outlook early Thursday despite delivering nearly double strong quarterly sales. Moderna stock tumbled.

Moderna is expected to release its fiscal second-quarter earnings next month, and analysts project a narrower loss.

Since May, a number of poultry farms around Australia have faced outbreaks of avian influenza, or bird flu. These outbreaks have been devastating for the poultry farms affected, necessitating large-scale culls, and have caused knock-on effects for the country’s egg supplies.

As part of the Biden admin's pandemic preparedness strategy, Moderna will develop an mRNA vaccine for H5N1

Moderna stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months.

Moderna recently outperformed the S&P 500, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Earlier this week, Moderna announced positive results for its phase 3 clinical trial of a combined vaccine against COVID and influenza.

The pharmaceutical company Moderna announced promising results from the ongoing trial of its new vaccine, mRNA-1083.

Clinical trials show two-in-one jab may bring about higher immune responses than separate inoculations

New vaccine could cut need for separate Covid and flu jabs

Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. But Moderna stock fell.